This model was chosen based on the tumor sensitivity upon TNF treatment and, moreover, on the fact that the fully-human fusion protein is currently being studied in pivotal trials for soft-tissue sarcoma indication, in combination with doxorubicin (EudraCT 2016-003239-38 and NCT03420014). Here, TNF is linked to neoplasm.